{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-286917","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2024-12-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.630285+00:00","generated_at":"2026-05-28T22:38:15.094680+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Corcept submits NDA for relacorilant to treat Cushing's syndrome","bullets":["NDA based on positive pivotal GRACE trial, Phase 3 GRADIENT, long-term extension and Phase 2 studies.","No drug-induced adrenal insufficiency, hypokalemia, QT prolongation, or progesterone receptor effects seen.","CEO Joseph Belanoff states relacorilant has potential to become standard of care for hypercortisolism."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-286917","json":"https://secwatch.observer/filing/0001193125-24-286917.json","markdown":"https://secwatch.observer/filing/0001193125-24-286917.md","text":"https://secwatch.observer/filing/0001193125-24-286917.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000119312524286917/0001193125-24-286917-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000119312524286917/d834253d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T22:38:15.094680+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}